CY1123543T1 - Παραγωγα διαμινοπυριδινης - Google Patents

Παραγωγα διαμινοπυριδινης

Info

Publication number
CY1123543T1
CY1123543T1 CY20201101039T CY201101039T CY1123543T1 CY 1123543 T1 CY1123543 T1 CY 1123543T1 CY 20201101039 T CY20201101039 T CY 20201101039T CY 201101039 T CY201101039 T CY 201101039T CY 1123543 T1 CY1123543 T1 CY 1123543T1
Authority
CY
Cyprus
Prior art keywords
present
compounds
diaminopyridine derivatives
jak
novel
Prior art date
Application number
CY20201101039T
Other languages
English (en)
Inventor
Gebhard Thoma
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1123543T1 publication Critical patent/CY1123543T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει νέα παράγωγα διαμινοπυριδίνης που επιδεικνύουν ιδιότητες ρύθμισης JAK. Η παρούσα εφεύρεση αναφέρεται επίσης σε φαρμακευτικές συνθέσεις που αποτελούνται από αυτές τις νέες ενώσεις, σε μεθόδους χρήσης των εν λόγω ενώσεων στη θεραπευτική αγωγή διαφόρων ασθενειών και διαταραχών που είναι επιρρεπείς σε διαμόρφωση JAK, και σε διαδικασίες για την παρασκευή των ενώσεων που περιγράφονται στη συνέχεια στο παρόν.
CY20201101039T 2015-11-26 2020-11-03 Παραγωγα διαμινοπυριδινης CY1123543T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15196542 2015-11-26
PCT/IB2016/057105 WO2017089985A1 (en) 2015-11-26 2016-11-24 Diamino pyridine derivatives

Publications (1)

Publication Number Publication Date
CY1123543T1 true CY1123543T1 (el) 2022-03-24

Family

ID=54705130

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101039T CY1123543T1 (el) 2015-11-26 2020-11-03 Παραγωγα διαμινοπυριδινης

Country Status (35)

Country Link
US (3) US10570096B2 (el)
EP (2) EP3757097B1 (el)
JP (1) JP6634157B2 (el)
KR (1) KR102097878B1 (el)
CN (2) CN112851578A (el)
AU (1) AU2016359438B2 (el)
BR (1) BR112018009540A2 (el)
CA (1) CA3005159A1 (el)
CL (1) CL2018001370A1 (el)
CO (1) CO2018005354A2 (el)
CR (1) CR20180285A (el)
CU (1) CU24506B1 (el)
CY (1) CY1123543T1 (el)
DK (1) DK3380465T3 (el)
DO (1) DOP2018000127A (el)
EA (1) EA035899B1 (el)
EC (1) ECSP18041731A (el)
ES (2) ES2916582T3 (el)
HK (1) HK1253530A1 (el)
HR (1) HRP20201662T1 (el)
HU (1) HUE052345T2 (el)
IL (1) IL259360B (el)
LT (1) LT3380465T (el)
MX (1) MX2018006495A (el)
MY (1) MY195905A (el)
PE (1) PE20181071A1 (el)
PH (1) PH12018501019A1 (el)
PL (2) PL3757097T3 (el)
PT (2) PT3380465T (el)
RS (1) RS60946B1 (el)
RU (2) RU2730007C2 (el)
SA (1) SA518391657B1 (el)
SG (1) SG11201803760VA (el)
SI (1) SI3380465T1 (el)
WO (1) WO2017089985A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018006495A (es) * 2015-11-26 2018-08-15 Novartis Ag Derivados novedosos de diamino piridina.
MX2021008303A (es) 2019-01-11 2021-10-13 Novartis Ag Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
EP2091918B1 (en) * 2006-12-08 2014-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2010058846A1 (ja) * 2008-11-21 2010-05-27 アステラス製薬株式会社 ４，６-ジアミノニコチンアミド化合物
WO2010061971A1 (ja) 2008-11-28 2010-06-03 興和株式会社 ピリジン－３－カルボキシアミド誘導体
AU2010206683B2 (en) 2009-01-23 2016-05-05 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN104955805B (zh) 2012-10-19 2018-11-09 霍夫曼-拉罗奇有限公司 Syk的抑制剂
BR112015009850A2 (pt) * 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
PL3495358T3 (pl) * 2012-11-08 2022-06-27 Bristol-Myers Squibb Company Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
JP2015014960A (ja) 2013-07-05 2015-01-22 ソニー株式会社 情報処理装置、および記憶媒体
JP2016539927A (ja) 2013-10-24 2016-12-22 アッヴィ・インコーポレイテッド Ｊａｋ１選択的阻害剤とその使用
CA2969590A1 (en) 2014-12-03 2016-06-09 Rxi Pharmaceuticals Corporation Methods for the treatment of alopecia areata utilizing gene modulation approaches
MX2018006495A (es) * 2015-11-26 2018-08-15 Novartis Ag Derivados novedosos de diamino piridina.

Also Published As

Publication number Publication date
CU24506B1 (es) 2021-04-07
EP3380465A1 (en) 2018-10-03
US20200140386A1 (en) 2020-05-07
PE20181071A1 (es) 2018-07-04
HK1253530A1 (zh) 2019-06-21
LT3380465T (lt) 2020-11-10
MX2018006495A (es) 2018-08-15
JP2019503343A (ja) 2019-02-07
SA518391657B1 (ar) 2021-02-22
RU2018122953A3 (el) 2020-01-29
AU2016359438A1 (en) 2018-05-31
KR20180067681A (ko) 2018-06-20
PL3757097T3 (pl) 2022-07-25
US20220177432A1 (en) 2022-06-09
US11274080B2 (en) 2022-03-15
US10570096B2 (en) 2020-02-25
AU2016359438B2 (en) 2019-05-02
IL259360A (en) 2018-07-31
HRP20201662T1 (hr) 2020-12-25
PH12018501019A1 (en) 2018-12-17
ES2829052T3 (es) 2021-05-28
CN108349937A (zh) 2018-07-31
EP3757097B1 (en) 2022-03-30
CL2018001370A1 (es) 2018-07-27
DOP2018000127A (es) 2018-10-31
ECSP18041731A (es) 2018-06-30
ES2916582T3 (es) 2022-07-01
CN108349937B (zh) 2021-02-09
BR112018009540A2 (pt) 2018-11-06
HUE052345T2 (hu) 2021-04-28
EP3380465B1 (en) 2020-08-05
PT3380465T (pt) 2020-10-23
MY195905A (en) 2023-02-27
CN112851578A (zh) 2021-05-28
RS60946B1 (sr) 2020-11-30
IL259360B (en) 2021-05-31
EA035899B1 (ru) 2020-08-28
RU2730007C2 (ru) 2020-08-14
US20180354904A1 (en) 2018-12-13
RU2018122953A (ru) 2019-12-26
EA201891258A1 (ru) 2018-10-31
JP6634157B2 (ja) 2020-01-22
WO2017089985A1 (en) 2017-06-01
CA3005159A1 (en) 2017-06-01
SG11201803760VA (en) 2018-06-28
EP3757097A1 (en) 2020-12-30
PL3380465T3 (pl) 2021-01-25
KR102097878B1 (ko) 2020-04-06
SI3380465T1 (sl) 2020-11-30
CR20180285A (es) 2018-07-16
DK3380465T3 (da) 2020-10-26
CO2018005354A2 (es) 2018-05-31
PT3757097T (pt) 2022-06-20
RU2020124922A (ru) 2020-08-10
CU20180044A7 (es) 2018-10-04

Similar Documents

Publication Publication Date Title
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CY1123996T1 (el) Υποκατεστημενα παραγωγα οξοπυριδινης
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1121874T1 (el) Παραγωγα μονο- ή διυποκατεστημενου ινδολιου ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CY1121972T1 (el) Mono- ή διυποκατεστημενα ινδολια ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
EA201691134A1 (ru) Новые ингибиторы глутаминазы
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
CY1124704T1 (el) Παραγωγα sobetirome
EA201890329A1 (ru) СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
EA201692109A1 (ru) Варианты антител к фактору d и их применение
CY1120715T1 (el) Παραγωγα ετεροαρυλιου βουτανικου οξεος ως αναστολεις lta4h
CY1121326T1 (el) Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες
EA201990400A1 (ru) Соединения и композиции и их применение
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CY1120185T1 (el) Υποκατεστημενα πυριδινικα παραγωγα χρησιμα ως αναστολεις c-fms κινασης